- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.01. | NSE - Protagenic Therapeutics, Inc.\new - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.01. | Protagenic Therapeutics wechselt nach NASDAQ-Delisting in den OTC-Handel | 6 | Investing.com Deutsch | ||
| 05.01. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
| 09.12.25 | Protagenic Therapeutics, Inc.: Results from Phase 1 Multiple-Dose Study of PT00114 | 350 | ACCESS Newswire | Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic... ► Artikel lesen | |
| 27.11.25 | Protagenic Therapeutics receives Nasdaq non-compliance letter | 5 | Seeking Alpha | ||
| 27.11.25 | Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | 432 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| 26.11.25 | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.11.25 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | Protagenic Therapeutics, Inc.\new - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 13.11.25 | Protagenic-Aktie steigt nach Abschluss der Phase-1-Dosierung | 7 | Investing.com Deutsch | ||
| 13.11.25 | Protagenic schließt Dosierungsphase in Phase-1-Studie für Medikament gegen Stresserkrankungen ab | 2 | Investing.com Deutsch | ||
| 13.11.25 | Protagenic completes dosing in phase 1 study of stress disorder drug | 2 | Investing.com | ||
| 13.11.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study | 248 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and... ► Artikel lesen | |
| 31.10.25 | Protagenic Therapeutics reicht Klage zur Rückabwicklung der Übernahme von Phytanix Bio ein | 2 | Investing.com Deutsch | ||
| 31.10.25 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 2 | SEC Filings | ||
| 22.08.25 | Protagenic Therapeutics provides update on Form 10-Q filing timeline and Nasdaq compliance | 1 | Seeking Alpha | ||
| 22.08.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance | 524 | ACCESS Newswire | Delay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing novel... ► Artikel lesen | |
| 22.08.25 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 4 | SEC Filings | ||
| 21.08.25 | Protagenic Therapeutics stock soars after advancing PT00114 to multiple-dose trial | 7 | Investing.com | ||
| 21.08.25 | Protagenic Therapeutics: Aktie schießt nach Meilenstein bei klinischer Studie in die Höhe | 6 | Investing.com Deutsch |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,040 | -5,63 % | Medigene: Zurückziehung - 18.11.2025 | ||
| VALNEVA | 4,200 | -2,64 % | Valneva Provides Update on Recommendations for Use of IXCHIQ in the United Kingdom | Lyon (France), February 13, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's... ► Artikel lesen | |
| BIOFRONTERA | 2,440 | +0,41 % | Biofrontera's Ameluz SNDA For Superficial Basal Cell Carcinoma Accepted By FDA | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 16,570 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,320 | -2,94 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,330 | +0,92 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,320 | -0,55 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp: Sirona Biochem downgraded to NEX | ||
| EDITAS MEDICINE | 1,478 | -0,57 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| VAXART | 0,450 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,925 | +5,60 % | Microbot Medical Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 4,978 | -0,56 % | Fiserv, Western Digital & ImmunityBio: Lohnen sich diese Aktien jetzt? | ||
| RECURSION PHARMACEUTICALS | 3,495 | -2,37 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.02.2026 | Das Instrument 1NN ES0105251005 NEINOR HOMES SA EO 6,38 EQUITY wird cum Kapitalmassnahme gehandelt am 09.02.2026 und ex Kapitalmassnahme am 10.02.2026 The instrument 1NN ES0105251005 NEINOR HOMES SA... ► Artikel lesen |
Das Unternehmen PROTAGENIC THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,56 % bei einem Aktienkurs von 1,588 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROTAGENIC THERAPEUTICS INC finden Sie auf Wallstreet Online.